Abstract: Abstract: Objective To observe the clinical efficacy of sacubitril / valsartan in patients with chronic heart failure. Methods Eighty-eight patients with chronic heart failure were enrolled in this study. They were divided into angiotensin receptor enkephalinase inhibitor (ARNI, n=47) group and control group (n=41). ARNI group was treated with sacubitril / valsartan, while control group received benazepril hydrochloride or valsartan. Data of body weight, 24-hour urine volume, dosage of diuretics, N-terminal pro-brain natriuretic peptid (NT-proBNP) level before treatment and 1 month after treatment, and cardiac structure and function before treatment and three months after treatment were compared between the two groups respectively. Results In ARNI group,the body weight, diuretic dosage and NT-proBNP level decreased, 24- hour urine volume increased, while left ventricular end-diastolic diameter (LVDD) and left atrium (LA) reduced, stroke volume (SV), cardiac output (CO), left ventricular ejection fraction (LVEF) and mitral diastolic blood flow velocity E peak and A peak ratio (E / A) increased after treatment compared to the baseline (all P＜0.05). Data of the NT-proBNP level decreased, 24-hour urine volume increased, LVDD and LA reduced, SV, LVEF and E/A increased (all P＜0.05) in ARNI group after treatment compared with those of the control group (P＜0.05). Cardiac function also improved in ARNI group after treatment compared to that of the control group (P＜0.05). Conclusion Compared with benazepril / valsartan, sacubitril/valsartan can further reduce water-sodium retention and improve cardiac function.

Key words: heart failure, valsartan, neprilysin, enzyme inhibitors, sacubitril/valsartan, benazepril